Gemcitabine in Patients With Solid Tumors and Renal Impairment: A Pharmacokinetic Phase I Study

AbstractThe purpose of this phase I study was to determine the pharmacokinetics and toxicity of gemcitabine in patients with advanced, recurrent, and/or metastatic cancer and renal impairment. Patients were entered in 4 groups estimated by EDTA-Cr51 plasma clearance (CLp, mL/min): ≥80; ≥60 and <80;